drugset / Trial / NCT06644781
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Timeline
- Start
- 2025-03-27
- Primary completion
- 2028-06-01
- Completion
- 2029-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Subject | Ifinatamab Deruxtecan | Other / unclassified | 12 mg/kg | Intravenous |
| Comparator | Irinotecan hydrochloride (HCl) | Unknown | — | Intravenous |
| Comparator | Paclitaxel | Small molecule | — | Intravenous |